Maxcyte Share Discussion Threads

[thetrotsky] 31/7/2021 11:40

AdamB178, Not sure where you are getting a closing price of $15.86 from. NASDAQ and Google Finance are both reporting $17 (about £12.20).

[trident5] 31/7/2021 10:14

Just a comment on the volumes, which no-one had mentioned. It was 3m of 13m shares issued.
As you say they were bought and sold at the higher prices. High fives.

[acuere] 31/7/2021 10:08

“trident530 Jul '21 - 22:37 - 866 of 869
0 0 1
A lot got flipped - over 3m traded.”

Or to counteract your usual tiresome negativity.

Good to see so many investors happy to buy at these higher prices.

[adamb1978] 31/7/2021 09:16

My view is that they'll stay on AIM whilst volumes are material. Personally I'm not expecting the AIM volumes to change much in absolute terms, but expect the the Nas listing to gradually takes up a greater proportion of the volume. That would be a good sign as it'll show more and more US investors coming into this, which in turn would be a sign of them succeeding

Technically its a cross-listing rather than a dual-listing which isnt so much of a burden so I'd only expect it to change whilst there is enough volume here

[nimbo1] 31/7/2021 08:10

Great start on Nasdaq in a tricky market :). Let’s hope it continues and if it plays out like Adam says above could be a good few years.

Donald I expect maxcyte to delist from aim in 12 months or so. No company wants a duel listing it’s a pain in the backside. Shares in aim are fully transferable to Nasdaq stock now when your brokers are set up to do it.

[donald pond] 30/7/2021 23:03

It's a bit harsh to draw the comparison with 4D, but MXCT have provided a prime example of how to manage a US listing: have a decent offering, get some cornerstone US institutions and have a CEO that talks their language. It's not complex, and one day doesn't make a summer, but I would be surprised if in very little time the US isn't leading the price action. Which is surely the point of the listing.

[trident5] 30/7/2021 22:37

A lot got flipped - over 3m traded.

[adamb1978] 30/7/2021 21:56

Agreed Donald. Ultimately where the share price is today could just be the shrapnel.

If the royalties from new drugs which result from their technology start to flow in 2-3 years time, then +/- $1 on the share price will be utterly insignificant

I dont feel that, at the moment, the share price reflects anything from those royalties, just an assumption about the milestone payments, and new similar payments, being earned

[donald pond] 30/7/2021 21:45

IG tells me a close at 1700 but no matter, it's all good. If MXCT captures the American imagination this will just be the start

[adamb1978] 30/7/2021 21:40

$15.86 close; underpins the rise in the UK to £11. Better to have a continued steady rise I guess than gapping up.

Pleasing that the listing has gone well, and that we have an additional pot of demand for the company

[shstt1] 30/7/2021 19:29

Cheers apad. Slipping now, back to uk close.

[assagai] 30/7/2021 19:21

Thanks Timbo, appreciated.

[timbo003] 30/7/2021 19:10

Header now augmented with comparative LSE vs Nasdaq daily chart for Maxcyte

[tictac] 30/7/2021 18:51

Nice to see a decent transition here.

[shstt1] 30/7/2021 18:32

Can you post a link cos I get msge google compare was discontinued 2016
Thanks

[chippyfriday] 30/7/2021 18:03

Thanks Apad

[adamb1978] 30/7/2021 17:56

Seems to be stabilising around the UK close of £11 = $15.40

[apad] 30/7/2021 17:51

Using Google compare shows the percentage change through the UK day and on into the US day in real(ish) time. It is a vivid representation.
Try it.
apad

[shstt1] 30/7/2021 17:42

Bloody ek volatile

[shstt1] 30/7/2021 17:40

Cnbc has wrong price

[shstt1] 30/7/2021 17:39

Easy enough to calc, Currently 10.7 based on 1.4

[adamb1978] 30/7/2021 17:34

Will be interesting to see how volumes change over coming weeks and months i.e. Aim vs Nasdaq